

November 15, 2019

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-005102-22/ Novartis Protocol ID CQVA149A2328

A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD patients with moderate to severe airflow limitation

Trial CQVA149A2328 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.